Eintrag weiter verarbeiten
Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open‐Label Trial
Gespeichert in:
| Zeitschriftentitel: | Arthritis & Rheumatology |
|---|---|
| Personen und Körperschaften: | , , , , , , , |
| In: | Arthritis & Rheumatology, 71, 2019, 10, S. 1616-1625 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Sanmarti, Raimon Veale, Douglas J. Martin‐Mola, Emilio Escudero‐Contreras, Alejandro González, Carlos Ercole, Liliana Alonso, Rocío Fonseca, João E. Sanmarti, Raimon Veale, Douglas J. Martin‐Mola, Emilio Escudero‐Contreras, Alejandro González, Carlos Ercole, Liliana Alonso, Rocío Fonseca, João E. |
|---|---|
| author |
Sanmarti, Raimon Veale, Douglas J. Martin‐Mola, Emilio Escudero‐Contreras, Alejandro González, Carlos Ercole, Liliana Alonso, Rocío Fonseca, João E. |
| spellingShingle |
Sanmarti, Raimon Veale, Douglas J. Martin‐Mola, Emilio Escudero‐Contreras, Alejandro González, Carlos Ercole, Liliana Alonso, Rocío Fonseca, João E. Arthritis & Rheumatology Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open‐Label Trial Immunology Rheumatology Immunology and Allergy |
| author_sort |
sanmarti, raimon |
| spelling |
Sanmarti, Raimon Veale, Douglas J. Martin‐Mola, Emilio Escudero‐Contreras, Alejandro González, Carlos Ercole, Liliana Alonso, Rocío Fonseca, João E. 2326-5191 2326-5205 Wiley Immunology Rheumatology Immunology and Allergy http://dx.doi.org/10.1002/art.40905 <jats:sec><jats:title>Objective</jats:title><jats:p>To evaluate the efficacy and safety of increasing the dose interval of subcutaneous tocilizumab (TCZ‐SC) in patients with rheumatoid arthritis (RA) who are in clinical remission.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>RA patients with active disease and an inadequate response to conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs) or to a biologic agent were entered into a single‐arm treatment phase with 162 mg of TCZ‐SC administered once weekly (TCZ‐SC 162 mg qw) as monotherapy or in combination with a csDMARD for 24 weeks. Patients who achieved clinical remission at weeks 20 and 24 were randomized to continue with the same regimen or to switch to 162 mg TCZ‐SC administered every 2 weeks (TCZ‐SC 162 mg q2w) for 24 weeks (open‐label). Patients with a Disease Activity Score in 28 joints (DAS28) of <2.6 were considered to be in clinical remission.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>In total, 179 (45%) of 401 patients in the single‐arm phase achieved clinical remission and were randomized to continue to receive TCZ‐SC 162 mg qw (n = 89) or to switch to TCZ‐SC 162 mg q2w (n = 90) for 24 weeks. At week 48, significantly more patients treated with TCZ‐SC 162 mg qw remained in clinical remission compared to patients who received TCZ‐SC 162 mg q2w (90% versus 73%; <jats:italic>P</jats:italic> = 0.004). The results of other efficacy measures revealed greater efficacy with TCZ‐SC 162 mg qw, but none of the efficacy outcomes in this group were significantly different from those in patients treated with TCZ‐SC 162 mg q2w, except for the mean change from baseline in the DAS28 score at week 48 (mean change −4.07 points [SD 1.29] versus −3.65 points [SD 1.35]; <jats:italic>P</jats:italic> = 0.034). Tolerability and safety parameters were similar between the treatment groups.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Increasing the dose interval of TCZ‐SC in patients with RA was associated with a lower likelihood of maintaining remission after 24 weeks and was not associated with better tolerability. However, most patients were able to sustain remission with a half‐dose of TCZ‐SC, and therefore this strategy deserves further investigation.</jats:p></jats:sec> Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open‐Label Trial Arthritis & Rheumatology |
| doi_str_mv |
10.1002/art.40905 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9hcnQuNDA5MDU |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9hcnQuNDA5MDU |
| institution |
DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 |
| imprint |
Wiley, 2019 |
| imprint_str_mv |
Wiley, 2019 |
| issn |
2326-5191 2326-5205 |
| issn_str_mv |
2326-5191 2326-5205 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
sanmarti2019reducingormaintainingthedoseofsubcutaneoustocilizumabinpatientswithrheumatoidarthritisinclinicalremissionarandomizedopenlabeltrial |
| publishDateSort |
2019 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Arthritis & Rheumatology |
| source_id |
49 |
| title |
Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open‐Label Trial |
| title_unstemmed |
Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open‐Label Trial |
| title_full |
Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open‐Label Trial |
| title_fullStr |
Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open‐Label Trial |
| title_full_unstemmed |
Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open‐Label Trial |
| title_short |
Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open‐Label Trial |
| title_sort |
reducing or maintaining the dose of subcutaneous tocilizumab in patients with rheumatoid arthritis in clinical remission: a randomized, open‐label trial |
| topic |
Immunology Rheumatology Immunology and Allergy |
| url |
http://dx.doi.org/10.1002/art.40905 |
| publishDate |
2019 |
| physical |
1616-1625 |
| description |
<jats:sec><jats:title>Objective</jats:title><jats:p>To evaluate the efficacy and safety of increasing the dose interval of subcutaneous tocilizumab (TCZ‐SC) in patients with rheumatoid arthritis (RA) who are in clinical remission.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>RA patients with active disease and an inadequate response to conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs) or to a biologic agent were entered into a single‐arm treatment phase with 162 mg of TCZ‐SC administered once weekly (TCZ‐SC 162 mg qw) as monotherapy or in combination with a csDMARD for 24 weeks. Patients who achieved clinical remission at weeks 20 and 24 were randomized to continue with the same regimen or to switch to 162 mg TCZ‐SC administered every 2 weeks (TCZ‐SC 162 mg q2w) for 24 weeks (open‐label). Patients with a Disease Activity Score in 28 joints (DAS28) of <2.6 were considered to be in clinical remission.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>In total, 179 (45%) of 401 patients in the single‐arm phase achieved clinical remission and were randomized to continue to receive TCZ‐SC 162 mg qw (n = 89) or to switch to TCZ‐SC 162 mg q2w (n = 90) for 24 weeks. At week 48, significantly more patients treated with TCZ‐SC 162 mg qw remained in clinical remission compared to patients who received TCZ‐SC 162 mg q2w (90% versus 73%; <jats:italic>P</jats:italic> = 0.004). The results of other efficacy measures revealed greater efficacy with TCZ‐SC 162 mg qw, but none of the efficacy outcomes in this group were significantly different from those in patients treated with TCZ‐SC 162 mg q2w, except for the mean change from baseline in the DAS28 score at week 48 (mean change −4.07 points [SD 1.29] versus −3.65 points [SD 1.35]; <jats:italic>P</jats:italic> = 0.034). Tolerability and safety parameters were similar between the treatment groups.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Increasing the dose interval of TCZ‐SC in patients with RA was associated with a lower likelihood of maintaining remission after 24 weeks and was not associated with better tolerability. However, most patients were able to sustain remission with a half‐dose of TCZ‐SC, and therefore this strategy deserves further investigation.</jats:p></jats:sec> |
| container_issue |
10 |
| container_start_page |
1616 |
| container_title |
Arthritis & Rheumatology |
| container_volume |
71 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792340789328609284 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:08:52.795Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Reducing+or+Maintaining+the+Dose+of+Subcutaneous+Tocilizumab+in+Patients+With+Rheumatoid+Arthritis+in+Clinical+Remission%3A+A+Randomized%2C+Open%E2%80%90Label+Trial&rft.date=2019-10-01&genre=article&issn=2326-5205&volume=71&issue=10&spage=1616&epage=1625&pages=1616-1625&jtitle=Arthritis+%26+Rheumatology&atitle=Reducing+or+Maintaining+the+Dose+of+Subcutaneous+Tocilizumab+in+Patients+With+Rheumatoid+Arthritis+in+Clinical+Remission%3A+A+Randomized%2C+Open%E2%80%90Label+Trial&aulast=Fonseca&aufirst=Jo%C3%A3o+E.&rft_id=info%3Adoi%2F10.1002%2Fart.40905&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792340789328609284 |
| author | Sanmarti, Raimon, Veale, Douglas J., Martin‐Mola, Emilio, Escudero‐Contreras, Alejandro, González, Carlos, Ercole, Liliana, Alonso, Rocío, Fonseca, João E. |
| author_facet | Sanmarti, Raimon, Veale, Douglas J., Martin‐Mola, Emilio, Escudero‐Contreras, Alejandro, González, Carlos, Ercole, Liliana, Alonso, Rocío, Fonseca, João E., Sanmarti, Raimon, Veale, Douglas J., Martin‐Mola, Emilio, Escudero‐Contreras, Alejandro, González, Carlos, Ercole, Liliana, Alonso, Rocío, Fonseca, João E. |
| author_sort | sanmarti, raimon |
| container_issue | 10 |
| container_start_page | 1616 |
| container_title | Arthritis & Rheumatology |
| container_volume | 71 |
| description | <jats:sec><jats:title>Objective</jats:title><jats:p>To evaluate the efficacy and safety of increasing the dose interval of subcutaneous tocilizumab (TCZ‐SC) in patients with rheumatoid arthritis (RA) who are in clinical remission.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>RA patients with active disease and an inadequate response to conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs) or to a biologic agent were entered into a single‐arm treatment phase with 162 mg of TCZ‐SC administered once weekly (TCZ‐SC 162 mg qw) as monotherapy or in combination with a csDMARD for 24 weeks. Patients who achieved clinical remission at weeks 20 and 24 were randomized to continue with the same regimen or to switch to 162 mg TCZ‐SC administered every 2 weeks (TCZ‐SC 162 mg q2w) for 24 weeks (open‐label). Patients with a Disease Activity Score in 28 joints (DAS28) of <2.6 were considered to be in clinical remission.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>In total, 179 (45%) of 401 patients in the single‐arm phase achieved clinical remission and were randomized to continue to receive TCZ‐SC 162 mg qw (n = 89) or to switch to TCZ‐SC 162 mg q2w (n = 90) for 24 weeks. At week 48, significantly more patients treated with TCZ‐SC 162 mg qw remained in clinical remission compared to patients who received TCZ‐SC 162 mg q2w (90% versus 73%; <jats:italic>P</jats:italic> = 0.004). The results of other efficacy measures revealed greater efficacy with TCZ‐SC 162 mg qw, but none of the efficacy outcomes in this group were significantly different from those in patients treated with TCZ‐SC 162 mg q2w, except for the mean change from baseline in the DAS28 score at week 48 (mean change −4.07 points [SD 1.29] versus −3.65 points [SD 1.35]; <jats:italic>P</jats:italic> = 0.034). Tolerability and safety parameters were similar between the treatment groups.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Increasing the dose interval of TCZ‐SC in patients with RA was associated with a lower likelihood of maintaining remission after 24 weeks and was not associated with better tolerability. However, most patients were able to sustain remission with a half‐dose of TCZ‐SC, and therefore this strategy deserves further investigation.</jats:p></jats:sec> |
| doi_str_mv | 10.1002/art.40905 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9hcnQuNDA5MDU |
| imprint | Wiley, 2019 |
| imprint_str_mv | Wiley, 2019 |
| institution | DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1 |
| issn | 2326-5191, 2326-5205 |
| issn_str_mv | 2326-5191, 2326-5205 |
| language | English |
| last_indexed | 2024-03-01T16:08:52.795Z |
| match_str | sanmarti2019reducingormaintainingthedoseofsubcutaneoustocilizumabinpatientswithrheumatoidarthritisinclinicalremissionarandomizedopenlabeltrial |
| mega_collection | Wiley (CrossRef) |
| physical | 1616-1625 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Arthritis & Rheumatology |
| source_id | 49 |
| spelling | Sanmarti, Raimon Veale, Douglas J. Martin‐Mola, Emilio Escudero‐Contreras, Alejandro González, Carlos Ercole, Liliana Alonso, Rocío Fonseca, João E. 2326-5191 2326-5205 Wiley Immunology Rheumatology Immunology and Allergy http://dx.doi.org/10.1002/art.40905 <jats:sec><jats:title>Objective</jats:title><jats:p>To evaluate the efficacy and safety of increasing the dose interval of subcutaneous tocilizumab (TCZ‐SC) in patients with rheumatoid arthritis (RA) who are in clinical remission.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>RA patients with active disease and an inadequate response to conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs) or to a biologic agent were entered into a single‐arm treatment phase with 162 mg of TCZ‐SC administered once weekly (TCZ‐SC 162 mg qw) as monotherapy or in combination with a csDMARD for 24 weeks. Patients who achieved clinical remission at weeks 20 and 24 were randomized to continue with the same regimen or to switch to 162 mg TCZ‐SC administered every 2 weeks (TCZ‐SC 162 mg q2w) for 24 weeks (open‐label). Patients with a Disease Activity Score in 28 joints (DAS28) of <2.6 were considered to be in clinical remission.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>In total, 179 (45%) of 401 patients in the single‐arm phase achieved clinical remission and were randomized to continue to receive TCZ‐SC 162 mg qw (n = 89) or to switch to TCZ‐SC 162 mg q2w (n = 90) for 24 weeks. At week 48, significantly more patients treated with TCZ‐SC 162 mg qw remained in clinical remission compared to patients who received TCZ‐SC 162 mg q2w (90% versus 73%; <jats:italic>P</jats:italic> = 0.004). The results of other efficacy measures revealed greater efficacy with TCZ‐SC 162 mg qw, but none of the efficacy outcomes in this group were significantly different from those in patients treated with TCZ‐SC 162 mg q2w, except for the mean change from baseline in the DAS28 score at week 48 (mean change −4.07 points [SD 1.29] versus −3.65 points [SD 1.35]; <jats:italic>P</jats:italic> = 0.034). Tolerability and safety parameters were similar between the treatment groups.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Increasing the dose interval of TCZ‐SC in patients with RA was associated with a lower likelihood of maintaining remission after 24 weeks and was not associated with better tolerability. However, most patients were able to sustain remission with a half‐dose of TCZ‐SC, and therefore this strategy deserves further investigation.</jats:p></jats:sec> Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open‐Label Trial Arthritis & Rheumatology |
| spellingShingle | Sanmarti, Raimon, Veale, Douglas J., Martin‐Mola, Emilio, Escudero‐Contreras, Alejandro, González, Carlos, Ercole, Liliana, Alonso, Rocío, Fonseca, João E., Arthritis & Rheumatology, Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open‐Label Trial, Immunology, Rheumatology, Immunology and Allergy |
| title | Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open‐Label Trial |
| title_full | Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open‐Label Trial |
| title_fullStr | Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open‐Label Trial |
| title_full_unstemmed | Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open‐Label Trial |
| title_short | Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open‐Label Trial |
| title_sort | reducing or maintaining the dose of subcutaneous tocilizumab in patients with rheumatoid arthritis in clinical remission: a randomized, open‐label trial |
| title_unstemmed | Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open‐Label Trial |
| topic | Immunology, Rheumatology, Immunology and Allergy |
| url | http://dx.doi.org/10.1002/art.40905 |